Prediction: My Top 2 Stocks to Buy Now Will Outperform the Stock Market Over the Next Decade

Source The Motley Fool

Key Points

  • The best stocks to invest in today hold strong competitive positions in rapidly expanding markets.

  • Market beaters often continue to soar to new highs.

  • 10 stocks we like better than Eli Lilly ›

Winners tend to keep on winning. This is a core principle of my investing philosophy that's helped me generate market-crushing returns for investors who've followed along with my stock picks. More importantly, I believe this principle can help you protect and grow your wealth in the coming years.

That's because the best businesses can deliver superior returns to their shareholders for far longer than the skeptics would have you believe. As legendary Hall of Fame football coach Vince Lombardi said, winning is a habit.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Companies and leadership teams that have achieved long-term success tend to cultivate powerful competitive advantages that drive further gains. In this regard, here are two proven winners that should continue to make their stock owners richer in the years ahead.

An investor reviewing financial statements and charts.

Image source: Getty Images.

Top stock to buy No. 1: Amazon

Few businesses are as well-positioned to profit from the artificial intelligence (AI) boom as Amazon (NASDAQ: AMZN).

AI is largely built in the cloud. Amazon Web Services (AWS) is a prime beneficiary of this global megatrend.

The leading cloud computing platform grew sales by 37% in the second quarter and is on pace to generate a whopping $169 billion in annualized revenue. Better still, Amazon's scale advantages and proprietary chip technology enable AWS to earn enviable operating margins of nearly 40%.

Looking ahead, CEO Andy Jassy thinks AWS could produce a staggering $600 billion in annual sales by 2036, fueled by soaring demand for AI services. Jassy also believes that AWS could eventually become a "trillion-dollar annual revenue business."

Amazon's massive e-commerce business also stands to benefit from advances in AI. The online retail colossus has long been a leader in robotic technology.

Amazon recently deployed its 1 millionth robot in its sprawling fulfillment network. As the world's largest operator of mobile robotics, Amazon is set to enjoy further gains in efficiency and profitability from new developments in physical AI and automation.

Importantly, Amazon's more than $160 billion in annual operating cash flow and $120 billion in cash reserves allow it to invest aggressively in these advanced technologies. During its second-quarter earnings call, Jassy said the cloud titan plans to spend a stunning $220 billion in 2026 alone to expand its computing capacity and e-commerce infrastructure to meet the "striking" demand for its offerings.

With multiple ways to cash in on the AI boom, Amazon is set to deliver handsome gains to its shareowners for at least another decade.

Top stock to buy No. 2: Eli Lilly

Eli Lilly's (NYSE: LLY) blockbuster GLP-1 medications make it easier for people to lose weight by controlling hunger. But the effects go far beyond just appearances.

Obesity can lead to a range of serious medical conditions, including heart disease, stroke, and diabetes. More than 100 million adults are obese in the U.S. alone, according to the Centers for Disease Control and Prevention (CDC).

Unsurprisingly, given their weight-loss and other health benefits, demand for Eli Lilly's GLP-1 drugs is surging. Sales of the healthcare giant's patented Mounjaro and Zepbound products soared 91% and 44%, respectively, to $9.9 billion and $4.9 billion in the second quarter.

Eli Lilly's customer base is set to grow far larger in the coming years. Its new GLP-1 pill, Foundayo, provides another, more convenient option for people who are uncomfortable with injectable medicines. At the same time, new Medicare drug coverage programs are making Eli Lilly's obesity medicines more affordable for many people.

With annual global sales of GLP-1 drugs projected to reach $190 billion by 2035, according to Morgan Stanley, Eli Lilly is well placed to grow its sales and profits at an above-average rate in the coming decade. For its part, Wall Street is projecting annualized earnings growth of roughly 22% over the next five years.

Eli Lilly may be a 150-year-old company, but it remains firmly in the vanguard of medical innovation. The pharma titan's best-in-class research and development program is a major competitive advantage and the foundation of its long-term success.

Should you buy stock in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $379,123!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,408,822!*

Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of October 11, 2026.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Eli Lilly. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia slid 7.7% after hours while AMD and Broadcom rose — the AI trade changed hands, it didn't breakNvidia closed Wednesday at 173.73, up 2.87%, then fell as much as 8.1% to 159.44 after reports that its board was preparing for a possible leadership change. The same session, the Philadelphia Semiconductor Index rose 5.7% with all 30 components higher, CoreWeave jumped 24.7% on 168% revenue growth, and Micron added 11.9%. If AI demand were being repriced, AMD and Broadcom would not be bid. This is a governance discount on one name, and 204.54 — the 200-day average — is the level that settles it.
Author  Irene Q.
Nov 12, Thu
Nvidia closed Wednesday at 173.73, up 2.87%, then fell as much as 8.1% to 159.44 after reports that its board was preparing for a possible leadership change. The same session, the Philadelphia Semiconductor Index rose 5.7% with all 30 components higher, CoreWeave jumped 24.7% on 168% revenue growth, and Micron added 11.9%. If AI demand were being repriced, AMD and Broadcom would not be bid. This is a governance discount on one name, and 204.54 — the 200-day average — is the level that settles it.
placeholder
Gold hit a one-year low while central banks bought 321 tonnes — the sellers were never the ones you thinkSpot gold closed at 3,876 on Thursday, down 2.8% and its lowest close in more than a year, with an intraday low near 3,852. The dollar is at a 19-month high of 103.21 and the 10-year yield is at 5.10%, so the price move is easy to explain. What is harder to explain is who sold: central banks bought 321 tonnes in Q3, the PBoC added for a 24th straight month, ETF holdings are near a record 4,256 tonnes, and roughly 95% of the futures selling came from non-reportable and sovereign-type accounts rather than hedge funds. This piece separates the two books that have to balance.
Author  Irene Q.
Nov 13, Fri
Spot gold closed at 3,876 on Thursday, down 2.8% and its lowest close in more than a year, with an intraday low near 3,852. The dollar is at a 19-month high of 103.21 and the 10-year yield is at 5.10%, so the price move is easy to explain. What is harder to explain is who sold: central banks bought 321 tonnes in Q3, the PBoC added for a 24th straight month, ETF holdings are near a record 4,256 tonnes, and roughly 95% of the futures selling came from non-reportable and sovereign-type accounts rather than hedge funds. This piece separates the two books that have to balance.
placeholder
Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
Author  Irene Q.
11 hours ago
Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
11 hours ago
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
11 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
goTop
quote